PeptideDB

Rp-8-Br-cAMPS sodium

CAS: 925456-59-3 F: C10H10BrN5NaO5PS W: 446.15

Rp-8-Br-cAMPS sodium is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS sodium occupies cAMP binding sites on P
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity Rp-8-Br-cAMPS sodium is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS sodium occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS sodium can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS sodium also inhibits insulin secretion[1][2][3].
Invitro Rp-8-Br-cAMPS (1 mM;4-6 小时) 可以完全阻断 2-chloroadenosine (HY-W008344) 抑制 LAK 细胞毒性的能力,以及显著减轻 2-chloroadenosine (HY-W008344) 对细胞因子产生的抑制作用[1]。Rp-8-Br-cAMPS (50-100 μM;2 分钟 ) 在 832/13 细胞 (来源于 INS-1 细胞) 中抑制胰岛素的分泌[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Rp-8-Br-cAMPS sodium 相关抗体:
In Vivo Rp-8-Br-cAMPS (1 mg;腹腔注射;10 天) 在小鼠逆转录病毒感染模型中可以改善小鼠的免疫功能[3]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS 925456-59-3
Formula C10H10BrN5NaO5PS
Molar Mass 446.15
Transport Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Reference [1]. Raskovalova T, et al. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol Res. 2006;36(1-3):91-9. [2]. Yang S, et al. Enhanced cAMP protein kinase A signaling determines improved insulin secretion in a clonal insulin-producing beta-cell line (INS-1 832/13). Mol Endocrinol. 2004 Sep;18(9):2312-20. [3]. Nayjib B, et al. In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice[J]. The Open Immunology Journal, 2008, 1(1).